Tag: cse:lxx

May 15, 2019

Lexaria’s DehydraTECHTM Formulation Delivers 475% More CBD to Bloodstream after 15 Minutes than Conventional Industry Formulations

Lexaria Bioscience Corp. (CSE:LXX, OTCQX:LXRP)  (the "Company" or "Lexaria"), a drug delivery platform innovator, has proven in animal testing that...
May 7, 2019

Lexaria Bioscience Announces CBD-Beverage Formulation License Agreement with Nevada-Based Company

Lexaria Bioscience Corp. (CSE:LXX, OCTQX:LXRP) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces that it has entered a...
April 25, 2019

Lexaria Bioscience Expands Advisory Board

Lexaria Bioscience Corp. (CSE:LXX, OCTQX:LXRP) (the "Company" or "Lexaria"), a drug delivery platform innovator, is pleased to announce new appointments...
April 24, 2019

Lexaria Bioscience Announces Beverage License Agreement with California-Based Cannabis Company

Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) announces that it has entered a definitive 5-year agreement, via its subsidiary Lexaria...
April 9, 2019

Lexaria Bioscience Renews Contracts with Senior Management and Cancels Options

Lexaria Bioscience Corp. (CSE:LXX, OTCQX:LXRP) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, announces that it has successfully negotiated...
February 26, 2019

Lexaria Bioscience Comments on FDA Statement on Novel Nicotine Replacement Therapies

Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, comments on the February 21, 2019...
February 21, 2019

Cardiovascular Performance Improvements including Lower Blood Pressure Discovered from Human Clinical Trial using Lexaria’s DehydraTECH(TM) Powered TurboCBD(TM) Capsules

Lexaria Bioscience Corp. (CSE:LXX, OTC:LXRP) (the "Company" or "Lexaria"), a drug delivery platform innovator, is pleased to announce additional significant...